Drugs / MMR GlaxoSmithKline
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01991899 Comparator | Feb → Dec 2015 | chickenpox, measles, mumps infectious disease, rubella | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMR GlaxoSmithKline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01991899 ↗ |
| Modality | Vaccine | “MMR vaccine (Bio-TV) will have the same composition (vaccine strains)” NCT01991899 ↗ |
| Route | Subcutaneous | “0,5 ml, subcutaneous, MMR GlaxoSmithKline” NCT01991899 ↗ |